Blood Disorders & Hematology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

This Phase 3 trial tested a new combination of venetoclax and azacitidine as a maintenance treatment for people with acute myeloid leukemia following a stem cell transplant. The study included 465 participants from several countries and has reported results. If this treatment proves effective, it could offer patients a way to improve survival rates compared to current supportive care after transplant.

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This Phase 3 study explored whether adding acalabrutinib to the standard combination of bendamustine and rituximab improves outcomes for patients newly diagnosed with mantle cell lymphoma. Although the trial is not recruiting new participants, its findings may help doctors decide on better treatment options that could lengthen the time patients live without the cancer worsening.

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

This early-phase trial is investigating a new cell therapy that uses immune cells trained to target lymphoma-specific markers in adults with Hodgkin or Non-Hodgkin lymphoma. The therapy aims to more precisely attack cancer cells, potentially helping patients whose disease returned or did not respond to standard treatments. The study is ongoing in the United States but not currently recruiting.

Glofitamab in Real Life

This study is looking at how well the immunotherapy drug Glofitamab works in everyday clinical settings for patients with large B-cell lymphoma. It focuses especially on those whose cancer has returned or not responded after previous treatments including CAR-T therapy. Recruiting in France, the trial aims to provide real-world information on safety and effectiveness for about 250 patients.

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

This study compares stem cell transplant to other disease-modifying treatments in children and young adults with sickle cell disease. The goal is to better understand which approach may improve quality of life and reduce complications over a three-year period. Recruitment is ongoing in the United States and Canada.

This week in blood disorders and hematology research, several important trials have reported or continue to explore new treatment options for blood cancers and sickle cell disease. Advances in maintenance therapy after stem cell transplant, precision cell therapies, and real-world immunotherapy experiences are key areas of focus. These studies help build a clearer picture of how to improve long-term outcomes and quality of life for patients facing these challenging conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.